225Ac Radiopharmaceuticals with Bismuth Sequestration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The clinical use of pharmaceutical compositions radiolabeled with Actinium 225 (225Ac) is limited due to the systemic release of daughter nuclides, particularly 213Bi, which causes radiotoxicity and radiochemical instability.
Innovation Solution
Incorporating a bismuth chelator, specifically a 213Bi chelator, into the 225Ac compound formulation, along with a target binding moiety linked to a chelating agent and an optional antioxidant, to form a pharmaceutical composition that sequesters released 213Bi and reduces toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If 225Ac radiopharmaceuticals are used for cancer therapy, then high alpha particle emission energies can destroy malignant cells, but daughter nuclides are systemically released causing radiotoxicity
Solution Approach 1:
A bismuth sequestering agent is introduced as an intermediary substance that selectively binds to 213Bi daughter nuclides after they are released from 225Ac decay. This mediator captures the harmful daughter products and prevents their systemic distribution to healthy tissues, thereby maintaining the therapeutic alpha particle emission while reducing radiotoxicity
Solution Approach 2:
The harmful 213Bi daughter nuclides are extracted from the systemic circulation through selective binding by the bismuth sequestering agent. The sequestering agent removes 213Bi from the biological system's general circulation and concentrates it in a controllable manner, separating the therapeutic function (alpha particles from 225Ac) from the toxic function (free 213Bi distribution)
2Reliability
If 225Ac is used in radioligand therapy, then cancer cells can be targeted and destroyed, but the molecular bonds of the chelator are broken due to high classical recoil energy of daughter products
Solution Approach 1:
The system is segmented into functional components: the 225Ac-chelator-targeting moiety complex handles tumor targeting, while the separately administered bismuth sequestering agent handles daughter nuclide management. This segmentation allows the chelator to focus on stable 225Ac binding for targeting without the burden of preventing daughter release, which is physically unavoidable due to recoil energy
Solution Approach 2:
The bismuth sequestering agent is administered in advance or concurrently with the 225Ac radiopharmaceutical to establish a protective mechanism before daughter nuclides are released. This prior cushioning ensures that when 213Bi is released from 225Ac decay, it is immediately available to bind with the sequestering agent, preventing its harmful distribution
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The addition of a bismuth sequestering agent significantly decreases the toxicity induced by 225Ac decay, allowing for safer and more effective use of 225Ac radiopharmaceuticals in cancer therapy.
Implementation Method 1
a bismuth sequestering agent, typically capable of sequestering Bi3+
Implementation Method 2
225Ac decay yields six principal radionuclides progeny in the decay cascade up to stable 209Bi. A single 225Ac (t1⁄2=9.9 d; 5.8 MeV α particle) decay yields net 4 alpha and 3 beta− decays.
Data Source
AI summary
The disclosure concerns a pharmaceutical composition comprising a 225Ac radiolabeled complex formed by a 225Ac radionuclide, and a target binding moiety linked to a chelating agent; and a bismuth sequestering agent, typically capable of sequestering Bi3+. The disclosure also concerns a method for preparing said pharmaceutical composition.